Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Pooled result · AFResult — go to the resultRelative risk 0.92 95% CI 0.80–1.06Authors' conclusion
Current evidences showed that SGLT2i may have no preventive effects on the risk of AF in patients with HF.
Study context
- Population
- Heart failure (HF) patients in RCTs of SGLT2i (PubMed and ClinicalTrails.gov searched until 27 November 2022)
- Participants
- 16,579 patients10 RCTs
- Comparison
- SGLT2i vs placebo
- SGLT2in = 8,292
- Placebon = 8,287reference
- Outcome
- AF
Methodological detailsRisk of bias and quality of evidence assessed with the Cochrane tool
- Risk of bias and quality of evidence assessed with the Cochrane tool
Pooled result
As reported in the abstract
Relative risk
0.92
95% CI 0.80–1.06
P = 0.23
Events by group
SGLT2ivs Placebo
RR 0.92 (95% CI 0.80–1.06); P = 0.23
Further pooled results
Atrial fibrillation (AF) by subgroup (type of SGLT2i, type of HF, duration of follow-up)
- Similar results in subgroup analyses regardless of SGLT2i type, HF type and follow-up duration
Original publication
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review. Cardiovasc Diabetol. Published 24 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →